微针介导基因递送原位编程装甲 CAR-巨噬细胞用于黑色素瘤免疫治疗
In Situ Programming of Armored CAR‐Macrophages by Microneedle‐Mediated Gene Delivery for Melanoma Immunotherapy
共递送 TYRP1 导向 CAR 与缺氧响应 scPD-L1 的 MNP 微针在 B16F10 黑色素瘤小鼠中原位编程出装甲 CAR-巨噬细胞,延缓肿瘤进展并延长生存。
原文摘要
出版方登记 · CrossrefDespite clinical advances in CAR‐T therapy and immune checkpoint blockade, effective immunotherapy for solid tumors remains limited by restricted immune‐cell access and an immunosuppressive tumor microenvironment. Chimeric antigen receptor macrophages (CAR‐M) provide an alternative strategy by combining antigen‐directed myeloid programming with local immune remodeling. A self‐locking microneedle platform incorporating mannose‐modified nanoparticles (MNPs) enables localized in situ programming of CAR‐expressing macrophages at melanoma sites. The platform co‐delivers a tumor‐antigen‐directed CAR and a hypoxia‐responsive anti‐PD‐L1 single‐chain variable fragment (scPD‐L1). Initial studies in B16F10‐OVA tumors establish antigen‐dependent CAR activity and coordinated local immune remodeling. Therapeutic efficacy is subsequently evaluated in parental B16F10 tumors using an endogenous tyrosinase‐related protein 1 (TYRP1)‐directed CAR. MNP(TYRP1/scPD‐L1) microneedles delay tumor progression, prolong survival, and promote coordinated myeloid and CD8 + T‐cell responses, while providing lower terminal tumor burden, greater local surface CAR + tumor‐associated macrophage abundance, and reduced systemic exposure compared with dose‐matched intratumoral administration. Reciprocal depletion further shows that CAR‐programmed macrophages contribute to the antigen‐directed myeloid response, whereas CD8 + T cells are major downstream effectors required for maximal and sustained tumor control. These findings establish a localized transcutaneous strategy that coordinates antigen‐directed myeloid programming with adaptive antitumor immunity.
页面未能读取全文,以上为出版方登记的摘要;方法与图表见原文
来源:Advanced Materials · doi.org